VIVE News and Press, Viveve Medical Inc. From 09/28/23

Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...

Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...

DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...

Viveve Medical Inc. (VIVE) is expected to report for quarter end 2023-06-30

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Jeppe Gustafsson / Shutterstock.com Tritium (NASDAQ: DCFC ) stock is rocketing higher on Tuesday thanks to a couple of pieces of positive news from the electric vehicle (EV) charging company. The first win...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Koshiro K / Shutterstock Xpeng (NYSE: XPEV ) stock is slipping on Tuesday after the EV maker cut the price of its cars to keep up with competitors. Starting those price cuts is the P7 sedan with a new st...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Ringo Chiu / Shutterstock Mullen Automotive (NASDAQ: MULN ) stock is falling on Tuesday as investors prepare for an upcoming shareholder meeting . A filing with the U.S. Securities and Exchange Commission...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Viveve Medical (NASDAQ: VIVE ) stock is falling hard on Tuesday after releasing results from the company’s latest clinical trial. That trial covers the use of the Viv...

Viveve Medical ( NASDAQ: VIVE ) treatment for female stress urinary incontinence (SUI) failed a pivotal trial and the company has decided to seek strategic alternatives and delist from Nasdaq. The Englewood, Colo.-based company added that due to its business prospects following th...

Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a...